Jubilant Life Sciences Limited operates as an integrated pharmaceutical and life sciences company worldwide. It has three segments: Pharmaceuticals, Life Science Ingredients, and Others. The company offers active pharmaceutical ingredients in the cardiovascular system, central nervous system, and anti-infective therapeutic areas; and develops dosage forms, including oral solid, injectable, and ophthalmic dosage forms. It is also involved in the contract manufacturing of sterile injectables, ointments, creams and liquids, allergy therapy products, and radiopharmaceutical products; manufacture and market of radiopharmaceuticals for the diagnosis, treatment, and monitoring of various diseases; business of licensing generic dosage forms and providing regulatory services to generic pharmaceutical companies; and supply of generic dosage forms and bulk chemicals, such as ethyl acetate, acetic anhydride, etc., as well as vitamins to the European markets. In addition, the company offers drug discovery services to pharmaceutical and biotech companies; and services in synthetic organic chemistry, combinatorial chemistry, medicinal chemistry, process research and development, scale up services, and GMP manufacturing-clinical supply to drug discovery companies in the United States, Europe, and internationally. Further, it sells and distributes advance intermediates, vitamins, life science chemicals, and fine ingredients in North America; and trades in advance intermediates, specialty ingredients, and nutrition products for the pharmaceutical, animal feed, and agrochemical industries in China. Additionally, the company operates a network of approximately 50 radiopharmacies in 22 states of the United States. The company was formerly known as Jubilant Organosys Limited and changed its name to Jubilant Life Sciences Limited in 2010. The company was incorporated in 1978 and is based in Noida, India. The ISIN of this stock is INE700A01033.